Latest releases

August 13, 2010 | 08:00
First half report 2010 - Lundbeck reports strongly increasing profits with EBIT growth of 30%

August 5, 2010 | 15:25
TEMPO study further demonstrates the benefits of Azilect® in early Parkinson's disease patients

May 27, 2010 | 08:30
First patients recruited in the extended phase III programme using Lu AA21004 in MDD

May 25, 2010 | 08:29
Lundbeck will submit an NDA for clobazam for patients with Lennox-Gastaut syndrome with the FDA before year end 2010

May 17, 2010 | 08:30
Positive pivotal results on escitalopram in Japan - Lundbeck's partner Mochida plans to file escitalopram for regulatory approval in first quarter 2011 at the latest

May 10, 2010 | 10:00
Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

May 6, 2010 | 08:00
First Quarter Report 2010 - Lundbeck delivers strong growth - and is off to a very good start to achieve full year guidance

April 22, 2010 | 14:25
H. Lundbeck A/S held its Annual General Meeting on 20 April 2010 at the company's registered office

April 16, 2010 | 14:00
Update on legal proceedings

April 6, 2010 | 10:00
Novel agent for treatment of Parkinson's disease - Lu AE04621 - enters Lundbeck's development pipeline

March 26, 2010 | 09:02
Notice of the annual general meeting

March 16, 2010 | 08:29
Desmoteplase enters clinical phase II in Japan in ischaemic stroke representing Lundbeck's first clinical programme in Japan

March 4, 2010 | 08:00
Fourth quarter and full year report 2009 - Lundbeck delivers 22 percent revenue growth for 2009 and meets financial expectations for 2009

March 3, 2010 | 08:30
Lundbeck and Takeda finalise plans to initiate phase III pivotal clinical trials with Lu AA21004 and Lu AA24530

February 25, 2010 | 10:24
Data from a post hoc analysis using desmoteplase in ischaemic stroke presented at the International Stroke Conference

February 24, 2010 | 10:00
Lundbeck expands the agreement with Teva to include marketing of Azilect® in selected Asian countries

January 7, 2010 | 12:08
The European Commission opens proceedings

March 19, 2010 | 09:02
Lundbeck appoints Senior Vice President for Business Development

March 15, 2010 | 09:00
Lundbeck appoints Senior Vice President for Legal

February 23, 2010 | 06:00
The search for future scientists begins

February 5, 2010 | 08:02
Lundbeck appoints Vice President of Investor Relations and Communications

January 28, 2010 | 08:00
Lundbeck appoints Vice President of Group Finance

January 11, 2010 | 07:56
Lundbeck and Teva launch Azilect® in France